£											
35	'i e	4				Docket Number (O)	ptional) CSI-101	ľ	Application Number		
	INFO	RMATIO	N DISCLOS VIRE	CITATION		Applicant(s)	CS1-101	L	10,0	90,632	
		(Use s	everal sheeps Debessa	Æ)		Clark Lum		— т	Group Art Unit		
			AUE N 9	MAX EX		Filing Date Mar	ch 6, 2002	ľ	•	1636	
			- NIS 11 3	33	U.S. PAT	ENT DOCUMEN		,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_,_			
*EXAMINER	T	T	UMENT NUMBER		0.0.171	ENT BOCOMEN	 			FII 1010	D. 1877
INITIAL	REF	DOC	UMENT NUMBER	DATE		NAME		CLASS	SUBCLASS	FILING IF APPRO	
90		US 5,004	1,681	04/02/91	Boyse e	t al.					
		US 5,061	1,620	10/29/91	Tsukan	ioto et al.			REC	RECEIVED	
		US 5,397	7,706	03/14/95	Соггеа	et al.			AUG	1 3 200	12
		US 5,39	9,493	03/21/95	Emerso	n et al.			TECH CEN	TER 160	0/2900
		US 5,541	1,103	07/30/96	Kanz e	al.					
		US 5,599	9,703	02/04/97	Davis e	t al.					
		US 5,610),056	03/11/97	Nakaha	ıta					
		US 5,635	5,387	06/03/97	Fei et a	l.					
		US 5,640	5,043	07/08/97	Emerso	n et al.					
		US 5,670),351	09/23/97	Emerso	n et al.					
		US 5,67	7,136	10/14/97	Simmo	ns et al.					
					FOREIG	N PATENT DOC	UMENTS				
	REF	DOC	UMENT NUMBER	DATE		COUNTRY		CLASS	SUBCLASS	Trans YES	NO NO
90	<u>'</u>	WO95/0	6112	03/02/95	PCT						
		WO97/1	7079	05/15/97	PCT						
		WO97/4	1224	11/0697	PCT						
		WO98/2	1313 '	05/22/98	PCT (i	n Japanese)					
		WO99/3	0723	06/24/99	PCT	·					
·					OTHER	DOCUMENTS	(Including A	uthor, Title,	Date, Pertinent Pa	iges, Etc.)	
94	2	AA 1	BB Standards and M	Ianuais available	e through	www.aabb.org.	•				
		Alm Eng Res	neida-Porada et al., raftment of Human earch 9:683-693 (20	"Evaluation of S Hematopoietic S 00).	Serum-Fre Stem Cells	e Culture Condi in the Human-t	itions Able t o-SHeep Xe	o Support nograft Mo	the Ex Vivo Exp odel," J. Hemato	pansion and the state of the st	i StenCell
EXAMINE	ER	\bigcirc_{o}	e Was	Ece-	>	DATE CONSID	ERED	11/24	104		
			considered, whether of this form with next			nce with MPEP Se	ction 609; Dr		 	in conform	ance and

Form PTO-A820 (also form PTO-1449) P09A/REV04

Patent and Trademark Office * U.S. DEPARTMENT OF COMMERCE

	•		7			Docket Number (Optionsi)		Application Number		
	TAIN		TION DIGGE OF	ola Park		HCSI-101		10/090,632		
	INFO)KMA	ATION DISCLOSU	essary)		Applicant(s) Clark Lum				
				AUG 0 9 2002	1	Filing Date		Group Art Unit		
				אָנָע מעק		March 6, 2002	į	. 1	1636	
		_		DATE DATE	U.S. PAT	ENT DOCUMENTS				
*EXAMINER INITIAL	REF		DOCUMENT NUMBER	DATE		NAME	CLASS	SUBCLASS	FILING D IF APPROP	
70-	ļ 	US	5,688,687	11/18/97	Palsson	et al.	,			
		us	5,766,951	06/16/98	Brown			DEC		
		us	5,807,686	09/15/98	Wagner	et al.			EIVE	- 1
		US	5,827,742	10/27/98	Scadder				1 3 2002	1
		US	5,866,400	11/24/98	Terstap	pen et al.		TECH CEN	ER 1600/	2900
		US	5,840,580	02/02/99	Palsson	et al.	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,			
		us	5,888,807	03/30/99	Palsson	et al.				
		us	5,914,108	06/22/99	Tsukam	oto et al.				
		US	5,945,337	08/31/99	Brown					
		us	5,985,653	11/16/99	Amstro	ng et al.				
		us	5,994,129	11/30/99	Armstr	ong et al.				
		, <u> </u>			FOREIG	N PATENT DOCUMENTS				
	REF		DOCUMENT NUMBER	DATE	-	COUNTRY	CLASS	SUBCLASS	Transia YES	NO NO
		wo	000/36090	06/22/00	PCT					
		<u> </u>								
					OTHER I	OOCUMENTS (Including A	uthor, Title,	Date, Pertinent Pa	ges, Etc.)	
<u></u>	J		Almici et al., "Umb Haematologica 80(5	ilical cord blood as a):473-9 (1995). F	source of	hematopoietic stem cells: f	rom resear	rch to clinical ap	plication,"	
Ve le		١	Bhatia et al., "Qua culture," J. Exp Me	ntitative analysis reve d 186(4):619-24 (1997	als expan	sion of human hematopoiet	ic repopula	ating cells after s	short-term e	x vivo
EXAMINE	R) or Wa	Jus		DATE CONSIDERED //	/24/0	4		
				her or not citation is in elect communication to a		ce with MPEP Section 609; Dr	aw line thro	ugh citation if not	in conforma	nce and

	/ e	.			Docket Number (Optional)	,	Application Number		
		DAK LONGON DEGOT COM	OTTO A TOTAL OR A		HCSC-101		10,0	090,632	·
	INFO	RMATION DISCLOST	Transit V	•	Applicant(s) Clark Lum				
İ		/ 6	9 2002		Filing Date		Group Art Unit		
		AUG D	9 2002		March 6, 2002	2		1636	
		\z.		U.S. PAT	ENT DOCUMENTS				
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	ADE WARE		NAME	CLASS	SUBCLASS	FILING IF APPRO	
ÁU		US 6,030,836	02/29/00	Thiede et al.					
		US 6,048,721	04/11/00	Armstrong et al.			RECE	VED	
		US6,096,532	08/01/00	Armstr	ong et al.		AUG 1 3	2002	
Τ						·			
						 TE (CH CENTER	1600/290	0
							ļ		
	•								
									•
									_
					`				
				FOREIG	N PATENT DOCUMENTS				
	REF	DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	Trans	
								YES	NO
						i			
		·							
				OTHER	DOCUMENTS (Including	Author, Title,	Date, Pertinent Po	iges, Etc.)	
	T	BioWhittaker Catal	ogue information on	x-vivo	10 serum free culture med	ia, www.biov	vhittaker.be/xv	ivointro. #	
\bigcirc	W						. 22		
94		Brown, R.A., et al., transplantation for Lymphoma 2:271-2	"High-dose etoposid resistant acute myelo 77 (1996).	e, cycloph oid leuken	osphamide and total body nia: a study by the North A	irradiation v American Ma	with allogeneic rrow Transpla	bone marro nt Group,"	w Leuk
EXAMINE		Toe W			DATE CONSIDERED	11/24	104		
EXAMINE	R. Inie		her or not citation is in	conforma	nce with MPEP Section 609; I		·	t in conforma	ance and
		iclude copy of this form with r							

	٠			Docket Number (Optional)	Application Number
	· -			HCSI-101	10/090,632
INT	PADMATIAN	N DISCLOSURI	a der la afforde	Applicant(s)	10/070,032
IINE	(I lee sev	veral sheets if necess	ZOAHOU Z	Clark Lum	
	(Ose se-	erai sneeis ij necess	21	Filing Date	Group Art Unit
			AUG 0 9 2002 🛣	March 6, 2002	1636
ANY MINER	1		<u>रु</u>	<u></u>	
*EXAMINER INITIAL			\' \'\'\	Title, Date, Pertinent Pages, Etc.)	
	Cells	n, et al., "Serum-1 15(3):237-45 (199	ree conditions for cells ca	ipable of producing long-term survi	val in lethally irradiated mice," Stem
7,5			*		
	Brown	n at al "Fy Vivo	Serum-Free Culture Co	nditions for the Maintenance Evna	nsion and Engraftment of Human CD34+
	Hema	topoletic Stem Ce	ells and Progenitors," Ca	ncer Research Therapy and Control	17:123-129 (1998).
1		-	_		
- 1	i				
	Brown		se etoposide, cyclophospi	hamide, and total body irradiation v	with allogeneic hone marrow
		plantation for pat	ients with acute myeloid lood 85(5) 1391-1395 (Ma	leuukemia in untreated first relanse	: a study by the North American Marrow
			••		
	Broxn	neyer et al., "Gro	wth characteristics and e	xpansion of human umbilical cord b	lood and estimation of its potential for
	transp	lantation in adult	ts," NAS USA 89:4109 (N	Ла́у 1992). ь	-
			<u>.</u>		
	Capm	any, et al., "Shor	rt-term, serum-free, static	c culture of cord blood-derived CD3	4+ cells: effects of FLT3-L and MIP1 75-682 (1999). 4
1	aipna	ON IN VILTO EXPAIR	sion of nematopoletic his	ogenitor cells," riaematologica 64:0	/5-682 (1999). 4
			· . · ' 'T		
	ļ	11 34			······································
ľ	Civin,	C, Stem Cells M	leeting Report, "Gene Th	erapy in Clinical Applications,"Ste	m cells 18:150-156 (2000). 4
					RECEIVED
-	Clinic	al Laboratory Im	provement Amendments	("CLIA") at http://www.cms.hhs.go	ov/clia/ AUG 1 3 2002
			•	•	" AUG I O FOOF
					TECH CENTER 1600/2900
	Cordb	olood Transplants	ation Study, Cord Blood	Bank Standard Operating Procedur	es (SOP) Chapter 4 Processing
İ	Procee	dures, Chapter 5 rations for COBL	Shipping Procedures, Un T CBU Thawing SOP, at	napter 6, Sample Testing and Chara http://spitfire.emmes.com/study/coi	cterization, Chapter 7 QualityAssessment,
		#HIVII3 IV	10001	mtp://spame.com.com.com.com.	
	Curre	ent Good Tissue P	ractice for Manufacturer (1271 (Fed. Reg. 6615): 1	s of Human Cellular and Tissue-Bas	ed Products; Inspection and Enforcement,
	1.00	366 Ituic 21	. 18/1 (Ptu: 110g; voloj	1301-1337 (11012002).	
	 				
			expansion of human hema	atopoietic progenitor cells in serum-	free StemProTM-34 Medium," Focus
	18(3):	62-67.	-	·	
	Smith	et al "Neutroph	il maturation of CD34+	cells from peripheral blood and bon	e marrow in serum-free culture medium
-	with P	IXY321 and gran	nulocyte-colony stimulati	ng factor (G-CSF), J Hematotherap	y 6(4):323-34 (Aug. 1997) ▼
	De Br	uyn et al., "Mod	ulation of human cord bl	ood progenitor cell growth by recon	nbinant human interleukin 3 (IL-3), IL-6, SCF) in serum-supplemented and
\	granu	locyte-macropha -free medium." S	ge colony stimulating factors of the colony stimulating factors (1846).	tor (GM-CSF) and stem cell lactor (SCF) in serum-supplemented and
\		Pilot monani,	,tem com 12(0),010 (1		
EXAMINER		1		DATE CONSIDERED	
	()ros	1 + #			124/04
	7/09	houra			124 104
		-	er or not citation is in confor t communication to applican	•	ne through citation if not in conformance and

P09B/REV04

	`	Docket Number (Optional) HCSI-101	Application Number
INFOR	RMATION DISCLOSURE CITATION	Applicant(s)	10/090,632
#11#	(Use several sheets if necessary)	Clark Lum	1
	(" AUS 0 9 2002 🕱)	Filing Date	Group Art Unit
-	\z. <u>\\</u>	March 6, 2002	1636
*EXAMINER INITIAL	OTHER DOCUMEN 3 . (Including Sathor, Til	itle, Date, Pertinent Pages, Etc.)	
131116	Denning-Kendall et al., "Is in vitro expansion of h	auman cord blood cells clinically releva	ant?"Bone Marrow Transplant 21:225
qu	(2/98).	4	`
	"Draft Document Concerning the Regulation of P Transplantation or Further Manufacture Into Inju	Placental/Umbilical Cord Blood Stem (ectable Products," FDA, D ocket No.	Cell products Intended for 96N-0002 (Dec. 95).
	Drouet et al., "Human liquid bone marrow culture	e in serum-free medium," Br. J. Haer	m. 73:143-147 (6/89).
	Durand et al., "Long-term generation of colony-for Lymphoma 11:263 (1993).	orming cells (FCFC) from CD34+ hum	an umbilical cord blood cells," Leuk
	Lymphoma 11:263 (1993).		RECEIVED
	Lifetechnologies Tech-Online "Serum-Free Media	a" at	AUG 1 3 2002
	www.lifetech.com/Content/Tech-Online/cell_cultur	re/product_description/stree8ny.pai.	TECH CENTER 1600/2900
	"Establishment Registration and Listing for Manu	ufacturers of Human Cellular and Tis	
	Rule, 63 Fed. Reg. 26744 (May 14, 1998). \	ulation vis vi hamita.	217
	FAHCT Standards and Manuals available through	h http://www.unmc.edu/Community/fa	ihct/orders.htm;
	"Human Cellular and Tissue-based Products," 21 2001).	1 CFR 1271 proposed revisions, Feder	al Register 66(5):1551-1559 (Jan. 8,
	"Draft Document Concerning the Regulation of Pt Transplantation or Further Manufacture into Inje	heripheral Blood Hematopoietic Stem (ectable Products" FDA (Feb. 96).	Cell Products Intended for
	Flake, et al. "In utero hematopoletic stem cell trai 94:2179-2191 (1999).	nsplantation: ontogenic opportunities	and biologic barriers," Blood
	Gilmore, et al., "Ex vivo expansion of human uim Exp Hematol 28(11):1295-305 (Nov. 2000).	bilical cord blood and peripheral bloo	id CD34(+) hematopoietic stem cells,"
	"Serum-Free Medium for the Support of Hemato	poietic Stem/Progenitor Cells," Hema	tology Research News 1(1): 1-2 (10/97)
		ME COLUMNIER	
EXAMINER	Jol Wala	DATE CONSIDERED	4/01
	al if citation considered, whether or not citation is in conform: lude copy of this form with next communication to applicant.	•	arough citation if not in conformance and

			To the Number (On Honol)	I
• •	ŧ	. 	Docket Number (Optional) HCSI-101	Application Number 10/090,632
INJ		ATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant(s) Clark Lum	20,070,002
			Filing Date	Group Art Unit
			March 6, 2002	1636
•EXAMINER INITIAL		OTHER DOCUMENTS . (Including Author, Ti		
AUD 0 9	THE SC3	International Society for Hematotherapy and Grat	ft Engineering (ISHAGE) at http://ww	w.ishage.org/.
PARTY CEMA	Zee.	Kelly, et al. "Umbilical cord blood stem cells: Ap Pediatrics 130:695-703) (1997).	plication for the treatment of patients	with hemoglobinopathies," J. •
			7 J. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1. 1.	
		Kobari, et al, "In vitro and in vivo evidence for the ex vivo expanded human CD34(+) cord blood cells	e long-term multilineage (myelola, b., l s," Exp Hematol 28(12):1470-80 (2000	NK, and T) reconstiution capacity of).
		Kogler et al., "The effect of different thawing meth umbilical cord blood primitive and committed pro	hods, growth factor combinations and genitors, "Bone Marrow Transplant 2	media on the ex vivo expansion of 1(3):233-41 (1998).
		ITxM Diagnostics, Hematopoletic Stem Cell Labor 5, 2001).	ratory, description of services, www.it	xm.org/CBB/hsc.htm, visited on Jan.
	1	Stem Cell Sciences Inc., Introducing the Joint Servicholas Ciobanu, M.D., F.A. C.P. & Associates; Swww.stem-cell.com/transplant	vices of Stem Cell Sciences, Inc. and th Stem Cell Sciences UCB Stem Cells Tr	e Oncology/Hematology Practice of ansplant Services described at
		Koller et al., "Clinical-scale human umbilical cord Marrow Transplant 21:65-63 (4/98) and at www.a	blood cell expansion in a novel automa aastrom.com.	ated perfusion culture system," Bone
				(
		Kurtzberg et al, "Unrelated placental blood in ma	arrow transplantation," Stem Cells 186	(2):153-4 (3/00).
		McCowage GB, et al, "Multiparameter-fluorescen primitive umbilical cord blood cells," et al., Exp I	ce activated cell sorting analysis of reti Hematol 26(4):288-98 (Apr 1998).	roviral vector gene transfer into
		Laver J et al., "Effects of CD34+ selection and T stem cell transplantation," Exp Hematol 23(14):14	cell immunodepletion on cord blood he	matopoietic progenitors: relevance to
		Life Technologies Catalogue No. 10639 StemPro-3	34 SFM media (Dec. 2000). V	RECEIVED
		Dist Accumulation and a second	1	AUG 1 3 2002
		Life Technologies Catalogue information on AIM	V StemPro.	TECH CENTER 1600/2900
EXAMINER	<u></u>	1	DATE CONSIDERED	
	<u>) a</u>	1 Witail		24/04
		citation considered, whether or not citation is in conform: copy of this form with next communication to applicant.		rough citation if not in conformance and

* "		•	Docket Number (Optional) HCSI-101	Application Number 10/090,632
INF	ORMA	ATION DISCLOSURE CITATION	Applicant(s)	10/090,032
	((Use several sheets if necessary)	Clark Lum	
			Filing Date March 6, 2002	Group Art Unit 1636
*EXAMINER	Γ		<u> </u>	1030
INITIAL		OTHER DOCUMENTS (Including Author, Title	le, Date, Pertinent Pages, Etc.)	
	3	Life Technologies Catalogue No. 10708, Stem Pro	Complete Methylcellulose Medium (D	ec. 2000) 🥎
< 01 B	5		•	'
	41			
AUG O 9		Progenitor Cell Therapy, LLC, description of servi	ces at www.progenitorcell.net/main.h	ntm., visited on Mar. 13, 2001.
	4	y		
(H.)	.65			
PARTY CEMA	RIK	Nakahata, T., "Cord blood transplantation and ex (1999).	vivo expansion of hematopoietic stem	cells ," Rinsho Byori, Suppl 10:54-62
		(1333).		
		Noga SJ, "Engineering hematopoietic graft s using 101:311-30 (1999).	elutriation and positive cell selection	to reduce GVHD," Cancer Treat Res
			_^*	·
İ			_	·
		Novelli et al, "Ex vivo culture of cord blood CD34 nonobese diabetic/severe combined immunodeficies	+ cells expands progenitor cell numbe	rs, preserves engraftment capacity in
Ì		10(18):2927-40 (1999). •	in mice, and empances retroviral trans	duction enterency, 11um Gene Ther
				•
		O'Neil, B, "Implementing a validation program in	a cord blood bank," J. Hematother 5	:139.43 (AVE-1999ED 6
				HECEIVED
				AUG 1 3 2002
		Pecora et al., Bone Marrow Transplant 25(7):797		-
		·	TE	CH CENTER 1600/2900
		Piacibello et al., "Extensive amplification and self- Blood, 89:2644-2453 (4/97).	renewal of human primitive hematop	oietic stem cells from cord blood,"
		5100d, 57.2044-2455 (4777). ¥		·
				·
		"Products for Hematopoietic Cell Culture," Quality	y Biological, Inc. (Dec. 9, 1996). , 1	
			-	
			,	:
		Qiu et al., "Ex vivo expansion of CD34+ Umbilical Patients," Exp Hematol 26:8:82 (Aug. 1-5, 1998).	Cord Blood Cells: May [be] eligible	for Transplantation in Adult
		attentis, Exp Hemator Solotos (rtag. 1-5, 1996).	•	•
		,	•	
		Qui, et al., "Experimental study on ex vivo expansi 21(8):417-20 (Aug. 2000).	on of CD(34)(+) umbilical cord blood	cells,"Zhonghua Zue Ye Zue Za Zhi
		11(0):117 20 (112g. 2000).	•	
		,		
		Qiu, et al., "Ex vivo expansion of CD34+ umbilica effect cytokines," J. Hematotherapy & Stem Cell R	il cord blood cells in a defined serum-	free medium (QBSF-60) with early
		disconstruction of inclination enapy of Stein Cell N	······································	
(
EXAMINER			DATE CONSIDERED	<i>-</i>
*		for hold of a)	11/2Y	109
EVAMINED. I	nitial if	citation considered, whether or not citation is in conforma	nee with MPFP Section 600: Draw line th	rough election if not in conformance and

P09B/REV04

not considered. Include copy of this form with next communication to applicant.

	4	Docket Number (Optional)	Application Number						
INFORM	IATION DISCLOSURE CITATION	HCSI-101 Applicant(s)	10/090,632						
INFORM	(Use several sheets if necessary)	Clark Lum							
	•	Filing Date	Group Art Unit						
		Mar. 6, 2002	1636						
*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, 1	Title, Date, Pertinent Pages, Etc.)							
1PG	"Serum-Free Cell Culture Media," Quality Biolo	gical.	RECEIVED						
		AUG 1 3 2002							
PALE PALEMENT	Quality Biological Brochure, "Serum Free Media	TECH CENTER 1600/2900							
PACEMEN									
	Querol et al., "Expansion of cord blood progenite	or cells," Bone Marrow Transplant 21	Suppl 3:S77-80 (1998). 🔮						
	Reems et al.,"Obtaining an accepted Investigation Transfusion 39:357-63 (1999).	nal New Drug application to operate a	ı umbilical cord blood bank,"						
	Sakabe et al.,"Haematopoietic action of flt3 ligar or c-kit tyrosine kinase receptor: comparison wi	nd on cord blood-derived CD34-positiventh of the cell factor," J Eur . Haematol	e cells expressing different levels ofit3 60(5): 297-306 (1998);						
	Shadduck et al., "Rose of Serum-Free Medium i (Meeting Report), Stem Cells 18:154-5 (2000);	n the Ex Vivo Expansion of Human Co	rd Blood Hematopoietic Stem Cells						
	Smith et al., "Neutrophil Maturation of CD34+ C Medium Supplemented with G-CSF," Granulocy	Cells from Peripheral Blood and Bone N tes and Monocytes, 2832, p.711a , Bax	Marrow in serum-Free Culture ter Healthcare Corp.						
	"Suitability Determination for Donors of Human 52696 (Sept. 30, 1999).	Cellular and Tissue-based Products,"	FDA Proposed Rule 64 Fed. Reg.						
	Takahira et al, "Flt3 ligand prolongs survival of CD34+++ human umbilical cord blood myeloid progenitors in serum-depleted culture medium," Ann Hematol 72(3):131-5 (1996). •								
	University of Minnesota's Cord Blood Transplant	tation STudy Protocol; http://server3.c	ancer.umn.edu/page/research/trsplant. • १						
	CryocyteTM Freezing Containers Product Site, p www.cryocyte.com/description/description.htm, v	product description, Nexell Therapeution is the second section of the second se	es Inc.						
1	Serum-Free Products and Serum Substitutes," P www.stemcell.com/stemcell/htm/product_pages/s	roduct Description, StemSpanTM, temspan.html, visited on February 27,	2001.						
EXAMINER	or Watas	DATE CONSIDERED							
	f citation considered, whether or not citation is in conform e copy of this form with next communication to applicant		rough citation if not in conformance and						

P098/REV04

	والمنطقة والمستحدث والمستحد والمستحد والمستحد والمستحد والمستحد والمستحد والمستحد والمستحد والمستحد		
	~	Docket Number (Optional) HCSI-101	Application Number 10/090,632
INFO	RMATION DISCLOSURE CITATION (Use several sheets if necessary)	Applicant(s) Clark Lum	
		Filing Date	Group Art Unit
- · · · · · · · · · · · · · · · · · · ·		Mar. 6, 2002	1636
*EXAMINER INITIAL	OTHER DOCUMENTS (Including Author, 7	litle, Date, Pertinent Pages, Etc.)	
OLR E	Van Zant et al., Expansion in bioreactors of huma Blood Cells 20(2-3):482-90 (1994).	an progenitor populations from cord blo	od and mobilized peripheral blood,
MIP IL S DUN	Verfaille et al., "Kinetics of engraftment of CD3 CD34(+) cells from bone marrow," Exp. Hematol	4)-) and CD34)+) cells from mobilized 1. 28:1071-1079 (2000). ,	blood differs from that of CD34(-)and
	Yamaguchi et al., Serum-free coculture system fo mouse-reconstituting cells using human bone man	or ex vivo expansion of human cord bloorrow primary stromal cells, Exp Hemat	od primitive progenitors and SCID tol 29(2):174-182 (2001).
	Yin et al., "AC133, a novel marker for human he	matopoietic stem and progenititor cells,	" Blood 90(12):5002-12 (1997).
	Yoshida et al., "Thrombopoietin alone stimulate multipotential progenitors in serum-free culture,"	s the early proliferation and survival of " Br J. Haematol 98(2):254-64 (1997).	human erythroid, myeloid and
	Zuck, TF, "The applicability of cGMP to cord bl	lood cell banking," J Hematotherapy 5	
	Biological Response Modifiers Advisory Committ www.fda.gov/ohrms/dockets/ac/98/transcpt/3475(ee Meeting November 13, 1998 at URL only).	AUG 1'3 2002
	Unrelated Allegenic Cord Blood Banking and Tra www.NHLBI.nih.gov/meetings/cobl_fyrhtm.sched	ansplant Forum (Aug. 14-15, 2000) at Iule only.	TECH CENTER 1600/2900 ,
	Weiss, et al., "Chemically defined Serum-Free Me Viruses," In Vitro 16(7):616-628 (1980).	edia for the Cultivation of Primary Cell	s and Their Susceptibility to
	PR Newswire, Aastrom Biosciences Awarded Two Therapy; Grants Support Development of New A Gene Modification of Human Stem Cells, (Oct. 7, 1 Transplant Program," Aastrom News Release (Ju	o NIH Grants for Umbilical Cord Blood pplications for Aastrom's Enabling Tec 1997); "Aastrom Biosciences Awarded I lly 27, 2000).	Transpinats and AIDS Gene hnologies for the Transplantation and NIH Grant to Support Cord Blood
	Aastrom Product Overview, Business Model, and www.aastrom.com; "Aastrom Biosciences Award Program," Aastrom News Release (Oct. 20, 1998)	ded Phase II SBIR Grant to Support Ur)8, available through publical Cord Blood Transplant
EXAMINER	Dae Watan	DATE CONSIDERED U/241	
EXAMINER: Init	ial if citation considered, whether or not citation is in conform	nance with MPEP Section 609: Draw line the	rough citation if not in conformance and

P09B/REV04

not considered. Include copy of this form with next communication to applicant.

HCSI-101



PATENT 🗦

N THE CHIEF STATES PATENT AND TRADEMARK OFFICE

In re the Application of:

LUM, CLARK

Serial No.: 10/090,632

Filed: March 6, 2002

For: SYSTEM AND METHOD FOR

DELIVERING UMBILICAL CORD-DERIVED TISSUE-MATCHED STEMS FOR TRANSPLANTATION RECEIVED

Art Unit:

1636

AUG 1 3 2002

Examiner: Not

Not Yet Assigned ECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants wish to make of record in the above-identified application the documents referenced on the attached Form PTO-1449. A copy of each reference is enclosed herewith.

The undersigned believes that this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Accordingly, Applicants do not believe that a fee is due for filing this paper. However, should a first action on the merits have been issued on the same day or before this Information Disclosure Statement is filed, please accept this Information Disclosure Statement under Rule 97(c) and charge the requisite Rule 17(p) fee to our Deposit Account No. 50-1390, under Order No. HCSI-101 and proceed to consider this Information Disclosure Statement.

Serial No.: 10,090,632

اع!

Art Unit: 1636

Attorney's Docket No.: HCSI-101

Page 2

It is respectfully requested that the information be expressly considered during the prosecution of this application, and that each reference be made of record therein and appear

among the "References Cited" on any patent to issue therefrom.

This submission does not represent that any referenced document is material or constitutes "prior art." If it should be determined that one or more of the referenced documents constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the reference or references.

WO98/21313, in Japanese, is cited as being directed to a method for culturing hematopoietic stem cells.

Applicants further reserve the right to take appropriate action to establish the patentablity of the disclosed invention over any referenced document, should it be applied against the claims of the present application.

SHAW PITTMAN LLP 1650 Tysons Boulevard McLean, VA 22102

Tel: 703/770-7900

Date: August 9, 2002

Respectfully submitted,

By:

Michelle Symarks

CLARK LUM

Registration No. 41,971

Document #: 1247411 v.1





HCSI-101

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Art Unit:

Examiner:

RECEIVED

SEP 26 2002

?

In re the Application of:

CLARK LUM

Serial No.: 10/090,632

Filed: March 6, 2002

For: SYSTEM AND METHOD FOR

DELIVERING UMBILICAL CORD-

DERIVED TISSUE-MATCHED

STEM CELLS FOR TRANSPLANTATION

TECH CENTER 1600/2900

Unknown

1636

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents Washington, D.C. 20231

Sir:

Applicants wish to make of record in the above-identified application the document or documents referenced on the attached Form PTO-1449. A copy of each reference is enclosed herewith.

The cited references are mentioned in the Search Report (copy enclosed) of applicant's corresponding International patent application and are believed relevant for at least that reason.

The undersigned believes that this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Accordingly, Applicants do not believe that a fee is due for filing this paper. However, should a first action on the merits have been issued on the same day or before this Information Disclosure Statement is filed, please accept this Information Disclosure Statement under Rule 97(c) and

Serial No.: 10/090,632

Art Unit: 1636

Attorney's Docket No.: HCSI-101

Page 2

charge the requisite Rule 17(p) fee to our Deposit Account No. 50-1390, under Order No. HCSI-

101 and proceed to consider this Information Disclosure Statement.

It is respectfully requested that the information be expressly considered during the

prosecution of this application, and that each reference be made of record therein and appear

among the "References Cited" on any patent to issue therefrom.

This submission does not represent that any referenced document is material or

constitutes "prior art." If it should be determined that one or more of the referenced documents

constitute "prior art" under United States law, Applicants reserve the right to present to the

Office the relevant facts and law regarding the appropriate status of the reference or references.

Applicants further reserve the right to take appropriate action to establish the patentablity

of the disclosed invention over any referenced document, should it be applied against the claims

of the present application.

SHAW PITTMAN LLP

1650 Tysons Boulevard McLean, VA 22102

Tel: 703/770-7645

Date: September 25, 2002

Respectfully submitted,

CLARK L

By:

Michelle S. Marks

Registration No. 41,971

MSM/lf 1274157

		"			Docket Number (Option HCSI		A	pplication Number	090,632	
è	INFO	PRMATION DISCLOSURE (Use several sheets if necessal			Applicant(s) CLARK LUM	101			70,002	
		1 w. w. w. w	"	!	Filing Date		C	roup Art Unit		
		• •	······		March 6,	, 2002		1	1636	
				U.S. PAT	ENT DOCUMENTS			,		
*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE		NAME		CLASS	SUBCLASS	FILING IF APPRO	
		01, 5 6/3								
		SEP 2 5 2002								
		THADEWARDS				R	ECEI	VED		
		TRAUC					SEP 26			
					•	T: }	CENTER	600/2900		
						1601	 \ \ \ \ \ \ \ \ \ \ \ \ \ 			
					,					
					· · · · · · · · · · · · · · · · · · ·					
			,					1		-
	-									
				FOREIGI	N PATENT DOCUMEN	NTS				
	REF	DOCUMENT NUMBER	DATE		COUNTRY		CLASS	SUBCLASS	Transl YES	ation NO
					·				1 50	- 10
								†		
				 						
	<u> </u>									
							ļ			
1		<u></u>		OTHER	DOCUMENTS (Inclu	uding A	uthor Title, D	ate, Pertinent Pa	age Ftc.)	
		The UCLA Umbilical Co November 1997, website	ord Blood Bank,		•					
<>)U	ا ر	November 1997, website	updated August	t 8, 2000, at	t www.cordblood.me	d.ucla.	.edu.			
	\dashv	New England Cord Bloo	od Bank, establis	hed 1995 a	t www.cordbloodban	ık.com				
			·							
EXAMINE	R	أبا بعد لر	Tilair	>	DATE CONSIDERED)	124/04			
		ial if citation considered, whether o			ce with MPEP Section 6		• • •	gh citation if not	in conforms	ince and

		Р,				Docket Number (Option HCSI-1-3		Application Number 10/	090,632	
J.	ÍŃFC	RMATION DISC (Use several sh				Applicant(s) CLARK LUM				
		(OSE SEVERAL SIN	eeis ij necessary			Filing Date		Group Art Unit		
				· · · · · · · · · · · · · · · · · · ·		March 6, 2	002		1636	
			· F		U.S. PATI	ENT DOCUMENTS				
EXAMINER INITIAL	REF	DOCUMENT N	UMBER	DATE		NAME	CLASS	SUBCLASS	FILING IF APPRO	
		OILE	ć							
		SEP 2 5 2002	39)	· · · · · · · · · · · · · · · · · · ·						·
		PADEMAN.	<u>\$</u>	•			DE		-	-
		PRADEWA					TIC (PEIVE	D	
			-	<u>'</u>			SE	P 2 6 2002		
		· .					TECH CE	VTER 1600/29	00	
										*
						,				
-					FOREIGN	N PATENT DOCUMENT	s			
	REF	DOCUMENT N	UMBER	DATE		COUNTRY	CLASS	SUBCLASS	Trans YES	lation NO
					ļ					
:				-		-				<u></u>
		<u> </u>								
							<u></u>	<u> </u>		
	,							Date, Pertinent Po	iges, Etc.)	
_		American A	ssociation of	Blood, establish	ied 1953, u	pdated June 12, 2002, s	it www.aabb.o	rg.		
C_{V}						•				
			25							
						·		•		
EXAMINE	R (Due (1 Int	a)		DATE CONSIDERED	11/24	101		
						ce with MPEP Section 609			t in conform	ance and

HCSI-101

0 5 2003

PATENT -

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re the Application of:

C. LUM

Serial No.: 10/090,632

Filed: March 6, 2002

For: SYSTEM AND METHOD FOR

DELIVERING UMBILICAL CORD-

DERIVED TISSUE-MATCHED

STEM CELLS FOR TRANSPLANTATION

Art Unit: 1636

Examiner: Not Yet Assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants wish to make of record in the above-identified application the document or documents referenced on the attached Form PTO-1449. A copy of each reference is enclosed herewith.

The Written Opinion (copy enclosed) is mentioned in the applicant's corresponding International patent application and is believed relevant for at least that reason.

The undersigned believes that this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits for the above-referenced application.

Accordingly, Applicants do not believe that a fee is due for filing this paper. However, should a first action on the merits have been issued on the same day or before this Information Disclosure Statement is filed, please accept this Information Disclosure Statement under Rule 97(c) and

Serial No.: 10/090,632

Art Unit: 1636

Attorney's Docket No.: HCSI-101

Page 2

charge the requisite Rule 17(p) fee to our Deposit Account No. 50-1390, under Order No. HCSI-101 and proceed to consider this Information Disclosure Statement.

It is respectfully requested that the information be expressly considered during the prosecution of this application, and that each reference be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This submission does not represent that any referenced document is material or constitutes "prior art." If it should be determined that one or more of the referenced documents constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of the reference or references.

Applicants further reserve the right to take appropriate action to establish the patentablity of the disclosed invention over any referenced document, should it be applied against the claims of the present application.

SHAW PITTMAN LLP 1650 Tysons Boulevard McLean, VA 22102

Tel: 703/770-7900

Date: September 3, 2003

Respectfully submitted,

C. LUM

By:

Registration No. 41,971

28970

PATENT TRADEMARK OFFICE

PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB

control number. Complete if Known Substitute for form 1449A/PTO 10/090,632 **Application Number** INFORMATION DISCLOSURE Filing Date 3/6/02 STATEMENT BY APPLICANT **First Named Inventor** Lum Art Unit 1636 (use as many sheets as necessary) Not Yet Assigned Examiner Name Attorney Docket Number HCSI-101 Sheet

		U.	S. PATENT DO	CUMENTS		
Examiner Cite		Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines,	
Initials	No. ¹	Number- Kind Code ² (if known)	MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages Relevant Figures Appear	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-	,			
		US-				
		US-				
		US-				
		US-				
		US-		***************************************		
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				

		FOREIGN F	PATENT DOCU	MENTS		
Examiner Initials	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where	T _e
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
96		PCT Written Opinion PCT/US02/07233		Biostar, LLC		
l l						
						\Box
						m

	Examiner Signature	Aue	Wode	Date Considered	1 /25/07	
--	-----------------------	-----	------	--------------------	----------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04.

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document.

Kind of document by the appropriate symbols as Indicated on the document under WiPO Standard ST. 16 if possible.

Applicant is to place a check mark here if English language Translation is attached.